These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33386733)

  • 1. Brief intervention medication therapy management: Establishment of an opioid misuse intervention model delivered in a community pharmacy.
    Kenney A; Cox N; Bryan MA; Cochran G
    Am J Health Syst Pharm; 2021 Feb; 78(4):310-319. PubMed ID: 33386733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A community pharmacy intervention for opioid medication misuse: A pilot randomized clinical trial.
    Cochran G; Field C; Karp J; Seybert AL; Chen Q; Ringwald W; Hruschak V; Chickering S; Kincman J; Jaber A; Tarter R
    J Am Pharm Assoc (2003); 2018; 58(4):395-403. PubMed ID: 29691197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial.
    Cochran G; Chen Q; Field C; Seybert AL; Hruschak V; Jaber A; Gordon AJ; Tarter R
    Drug Alcohol Depend; 2019 Dec; 205():107570. PubMed ID: 31689641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing opioid medication misuse at point of service in community pharmacy: A study protocol for an interdisciplinary behavioral health trial.
    Cochran G; Shen J; Cox N; Field C; Carlston K; Sengpraseut B; White A; Okifuji A; Jackman C; Haaland B; Ragsdale R; Gordon AJ; Tarter R
    Contemp Clin Trials; 2022 May; 116():106759. PubMed ID: 35417771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies.
    Rao D; Ford JH; Shiyanbola OO
    Addict Sci Clin Pract; 2024 Apr; 19(1):27. PubMed ID: 38589965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of a mental health medication management intervention in Australian community pharmacies: Facilitators and challenges.
    Hattingh HL; Kelly F; Fowler J; Wheeler AJ
    Res Social Adm Pharm; 2017; 13(5):969-979. PubMed ID: 28583302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral, mental, and physical health characteristics and opioid medication misuse among community pharmacy patients: A latent class analysis.
    Cochran G; Hruschak V; Bacci JL; Hohmeier KC; Tarter R
    Res Social Adm Pharm; 2017 Nov; 13(6):1055-1061. PubMed ID: 27876595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C.
    Meyerson BE; Agley JD; Jayawardene W; Eldridge LA; Arora P; Smith C; Vadiei N; Kennedy A; Moehling T;
    Res Social Adm Pharm; 2020 May; 16(5):699-709. PubMed ID: 31611071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription opioid use: Patient characteristics and misuse in community pharmacy.
    Cochran G; Bacci JL; Ylioja T; Hruschak V; Miller S; Seybert AL; Tarter R
    J Am Pharm Assoc (2003); 2016; 56(3):248-256.e6. PubMed ID: 27053277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Opioid Misuse Among Rural Community Pharmacy Patients: Pilot Study for Screening and Implications for Future Practice and Research.
    Cochran GT; Engel RJ; Hruschak VJ; Tarter RE
    J Pharm Pract; 2017 Oct; 30(5):498-505. PubMed ID: 27402634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a framework of care for opioid medication misuse in community pharmacy.
    Cochran G; Gordon AJ; Field C; Bacci J; Dhital R; Ylioja T; Stitzer M; Kelly T; Tarter R
    Res Social Adm Pharm; 2016; 12(2):293-301. PubMed ID: 26048710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Implementation-Focused Qualitative Exploration of Pharmacist Needs Regarding an Opioid Use Disorder Screening and Brief Intervention.
    Rao D; McAtee C; Mercy M; Shiyanbola OO; Ford JH
    Subst Use Addctn J; 2024 Jan; 45(1):24-32. PubMed ID: 38258852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
    Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
    J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy.
    Nielsen S; Sanfilippo P; Picco L; Bruno R; Kowalski M; Wood P; Larney S
    Int J Clin Pharm; 2021 Apr; 43(2):420-429. PubMed ID: 32533428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.
    Wu LT; Mannelli P; John WS; Anderson A; Schwartz RP
    Subst Abuse Treat Prev Policy; 2023 Sep; 18(1):55. PubMed ID: 37697326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacists Who Screen and Discuss Opioid Misuse With Patients: Future Directions for Research and Practice.
    Cochran G; Field C; Lawson K
    J Pharm Pract; 2015 Aug; 28(4):404-12. PubMed ID: 24532819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The misuse of codeine containing medicines: Perceptions and behaviours of qualified pharmacy professionals.
    Bronkhorst E; Adamjee M; Poka M
    S Afr Fam Pract (2004); 2024 May; 66(1):e1-e7. PubMed ID: 38832385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Experience and Satisfaction with Opioid-Related Screening and Intervention in North Dakota Community Pharmacies.
    Lothspeich E; Werremeyer A; Chase S; Huseth-Zosel A
    J Pharm Pract; 2023 Oct; 36(5):1217-1224. PubMed ID: 35704458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.